LBF20406AM34: Difference between revisions

No edit summary
 
No edit summary
 
(21 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{Lipid/Header}}
{{Hierarchy|{{PAGENAME}}}}
{{Hierarchy|{{PAGENAME}}}}


Line 4: Line 6:
|LipidBank=XPR7051
|LipidBank=XPR7051
|LipidMaps=LMFA08020037
|LipidMaps=LMFA08020037
|SysName=N- ( (S) - (+) -2-hydroxypropyl) alpha ,alpha-dimethylarachidonoyl amide
|SysName=N-d-2S-Hydroxypropyl-alpha,alpha-dimethyl- (cis-5,cis-8,cis-11,cis-14) -eicosatetraenoylamine
|Melting Point=colorless oil <<7001>>
|Common Name=&&N- (S) - (+) -2-Hydroxypropyl-alpha,alpha-dimethylarachidonoylamide&&N- (S) - (+) -2-Hydroxypropyl-alpha,alpha-dimethyl- (5Z,8Z,11Z,14Z) -eicosatetraenoylamine&&
|NMR Spectra=<SUP><FONT SIZE=-1>1</FONT></SUP>H NMR (CDCl3) <FONT FACE="Symbol">d</FONT>5.95 (br s, lH), 5.30-5.42 (m, 8H), 3.92-3.96 (m, lH), 3.40-3.50 (m, lH), 3.02-3.23 (m, lH), 2.70-2.95 (m, 7H), 2.20-2.28 (m, lH), 2.00-2.15 (m, 4H), 1.70-1.75 (m, 2H) 1.20-1.52 (series of m, 14H), 0.89 (t, J=6.7Hz, 3H). <<7001>>
|Melting Point=colorless oil [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]]
|NMR Spectra=^1 H NMR (CDCl3) delta 5.95 (br s, lH), 5.30-5.42 (m, 8H), 3.92-3.96 (m, lH), 3.40-3.50 (m, lH), 3.02-3.23 (m, lH), 2.70-2.95 (m, 7H), 2.20-2.28 (m, lH), 2.00-2.15 (m, 4H), 1.70-1.75 (m, 2H) 1.20-1.52 (series of m, 14H), 0.89 (t, J=6.7Hz, 3H). [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]]
|Source=
|Chemical Synthesis=This compound was synthesized from arachidonic acid and (S)-(+)-l-amino-2-propanol. Yield is 57 %. [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]]
|Metabolism=
|Biological Activity=Binding to the brain cannabinoid receptor (CBl), Ki(nM)= 46.6±2.2 [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]]
}}
}}
{{Lipid/Footer}}

Latest revision as of 04:48, 21 October 2010

LipidBank Top
(トップ)
Fatty acid
(脂肪酸)
Glycerolipid
(グリセロ脂質)
Sphingolipid
(スフィンゴ脂質)
Journals
(雑誌一覧)
How to edit
(ページの書き方)


Upper classes: LB LBF



N- (S) - (+) -2-Hydroxypropyl-α,α-dimethylarachidonoylamide
LBF20406AM34.png
Structural Information
N-d-2S-Hydroxypropyl-α,α-dimethyl- (cis-5,cis-8,cis-11,cis-14) -eicosatetraenoylamine
  • N- (S) - (+) -2-Hydroxypropyl-α,α-dimethylarachidonoylamide
  • N- (S) - (+) -2-Hydroxypropyl-α,α-dimethyl- (5Z,8Z,11Z,14Z) -eicosatetraenoylamine
Formula C25H43NO2
Exact Mass 389.329379625
Average Mass 389.61446
SMILES CC(C)(C(=O)NC[C@H](C)O)CCC=CCC=CCC=CCC=CCCCCC
Physicochemical Information
colorless oil Sheskin_T et al.
This compound was synthesized from arachidonic acid and (S)-(+)-l-amino-2-propanol. Yield is 57 %. Sheskin_T et al.
Binding to the brain cannabinoid receptor (CBl), Ki(nM)= 46.6±2.2 Sheskin_T et al.
Spectral Information
Mass Spectra
UV Spectra
IR Spectra
NMR Spectra 1H NMR (CDCl3) δ 5.95 (br s, lH), 5.30-5.42 (m, 8H), 3.92-3.96 (m, lH), 3.40-3.50 (m, lH), 3.02-3.23 (m, lH), 2.70-2.95 (m, 7H), 2.20-2.28 (m, lH), 2.00-2.15 (m, 4H), 1.70-1.75 (m, 2H) 1.20-1.52 (series of m, 14H), 0.89 (t, J=6.7Hz, 3H). SheskinTet al.
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF20406AM34 See above. Sheskin_T et al. 1997